FindMyKOL
Clinical trialNCT07021209RecruitingPhase 1Interventional

GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases

NCT07021209 is a phase 1 interventional trial sponsored by Grit Biotechnology. As of 18 Nov 2026, it is recruiting participants. It studies GT719 Injection in Neurological Autoimmune Diseases. The registry lists an enrollment of 30 participants at 1 site in 1 country. The registry lists a start date of 14 Jan 2025 and a primary completion date of 13 Jan 2028. One of its registered investigators has a FindMyKOL profile.

SponsorGrit BiotechnologyEnrollment30Neurological Autoimmune Diseases
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT07021209
FieldValue
Registry IDNCT07021209
StatusRecruiting
PhasePhase 1
Study typeInterventional trial
Lead sponsorGrit Biotechnology
Enrollment30
Registered sites1
Countries1
ConditionsNeurological Autoimmune Diseases
DrugsGT719 Injection
Start14 Jan 2025
Primary completion13 Jan 2028
Study completion13 Jan 2028
Last update posted11 Sept 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is an open-label, prospective, exploratory clinical trial that includes a dose escalation phase and a dose expansion phase, aimed at evaluating the safety, cell dynamics, and preliminary efficacy of GT719 cells in adult participants with recurrent/refractory antibody-mediated neurological immune diseases.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China1 site, 1 recruiting
  • Tongji Hospital Affiliated To Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei

    Chuan QinDaishi TianWei Wang →
    Recruiting

Sites by country

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

GT719 Injection
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT07021209

Each answer restates registry values shown on this page.

What is NCT07021209?

NCT07021209 is a phase 1 interventional trial sponsored by Grit Biotechnology. It studies GT719 Injection in Neurological Autoimmune Diseases.

Is NCT07021209 recruiting?

As of 18 Nov 2026, it is recruiting participants. 1 of its 1 sites list their own status as recruiting.

Who leads NCT07021209?

The registry names Chuan Qin (principal investigator, Tongji Hospital), Daishi Tian (principal investigator, Tongji Hospital) and Wei Wang (principal investigator, Tongji Hospital) as overall officials.

Where does NCT07021209 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: China.

Which drugs does NCT07021209 study?

The registered drug and biological interventions are GT719 Injection.

When is NCT07021209 expected to complete?

The registry lists a primary completion date of 13 Jan 2028 and a study completion date of 13 Jan 2028. The sponsor last updated the record on 11 Sept 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.